Developing a Disease-Modifying Therapy for CMT1A and DMD
Overview
MyoTherix, Inc. is a clinical stage, biopharmaceutical company focused on the development of innovative therapies for patients suffering from Duchenne muscular dystrophy and other muscle disorders for which there are no treatments.
Research focus: Anti-inflammatory and anti-osteoporosis. MyoTherix’s lead clinical research program focusses on targeting the P2X7 pathway to improve muscle function and bone health and potentially reduce the side-effects from steroid use. The MyoTherix pre-clinical research program focusses on improving both cardiac and skeletal muscle function, reducing inflammation, and facilitating new muscle regeneration.
Our Approach
MyoTherix exclusively licensed MT-002 from AstraZeneca and identified CMT1A and DMD as key indications for clinical development.
In previous Phase I and Phase II clinical studies (in more than 400 patients), MT-002 was generally well tolerated across a wide range of doses and demonstrated high oral bioavailability with pharmacokinetics consistent with once-daily oral dosing, and pharmacodynamics consistent with 100% receptor blockade for 24 hours at a dose of approximately 5 mg/Kg.
Location
29540 Kohoutek Way, Union City, CA 94587
Contact Us
Want to learn more about MyoTherix or have a question about our approach? Use the contact form and let’s start a conversation.